A randomized, multicenter, phase II trial of camrelizumab (Cam) with and without metastasis-directed therapy (MDT) in recurrent/metastatic nasopharyngeal carcinoma (R/M-NPC).

被引：0
|
作者：
Zhang, Xin [1 ]
Yan, Jin [2 ]
Lei, Qianqian
Zhang, Lu
Yang, Jieying
Tan, Sze Huey
Chua, Melvin L. K.
Wang, Ying
Sui, Jiangdong
机构：
[1] Chongqing Univ, Coll Med, Chongqing, Peoples R China
[2] Natl Canc Ctr Singapore, Singapore, Singapore
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 23_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.23_suppl.141
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：141 / 141
页数：1
相关论文
共 50 条
  • [31] A multicenter, randomized, double-blind, placebo-controlled phase Ill study of anlotinib or placebo in combination with gemcitabine and cisplatin (GP) as first -line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC).
    Yang, Yunpeng
    Huang, Yan
    Fang, Wenfeng
    Ma, Yuxiang
    Cai, Qingqing
    Li, Zhi-Ming
    Zhao, Hongyun
    Zhao, Yuanyuan
    Zhou, Ting
    Hong, Shaodong
    Zhang, Yaxiong
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] Apatinib for locoregionally recurrent or metastatic nasopharyngeal carcinoma after failure of first-line chemotherapy: A multicenter, phase II trial.
    Jiang, Wei
    Liang, Jinghui
    Pan, Yufei
    Ruan, Xiaolan
    Cai, Rui
    He, Zhuokai
    Chen, Qiuqiu
    Zhang, Rongjun
    Yang, Xi
    Liu, Meilian
    Zhao, Bo
    Liu, Zhengchun
    Niu, Zhijie
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Preliminary efficacy and safety of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase II clinical trial.
    Ji, Dongmei
    Sang, Youzhou
    Liu, Xin
    Guo, Yanjing
    Yang, Yanan
    Chen, Guangliang
    Dong, Shu
    Wang, Yulong
    He, Xiayun
    Ying, Hongmei
    Lu, Xueguan
    Wang, Yu
    Hu, Chaosu
    Ji, Qinghai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study
    Mountzios, G.
    Dimopoulos, M. A.
    Bamias, A.
    Vourli, G.
    Kalofonos, H.
    Aravantinos, G.
    Fountzilas, G.
    Papadimitriou, C. A.
    ANNALS OF ONCOLOGY, 2009, 20 (08) : 1362 - 1368
  • [35] Multicenter Phase II study of MK-2206 in previously treated patients (pts) with recurrent and metastatic nasopharyngeal carcinoma (NPC): Mayo Clinic Phase II Consortium (Protocol: MC1079)
    Ma, Brigette B.
    Goh, Boon Cher
    Lim, Wan Teck
    Tan, Eng Huat
    Lopes, Gilberto de Lima
    Hui, Edwin P.
    King, Ann D.
    Lo, Kwok Wai
    Loong, Herbert
    Li, Leung
    Foster, Nathan
    Kam, Michael
    Leung, Sing Fai
    Erlichman, Charles
    Chan, Anthony T. C.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [36] A randomized, multicenter phase HI clinical trial comparing gemcitabine and eisplatia with 5-fluoronracil and cisplatin in the treatment of recurrent or metastatic nasopharyngeal carcinoma.
    Zhang, Li
    Huang, Yan
    Wu, Xuan
    Liang, Wenhua
    Fang, Wenfeng
    Hu, Zhihuang
    Qin, Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Safety analysis of a phase III randomized trial of chemotherapy with or without bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Argiris, Athanassios
    Li, Shuli
    Savvides, Panayiotis
    Forastiere, Arlene A.
    Burtness, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)
    Yoshida, Soichiro
    Takahara, Taro
    Arita, Yuki
    Ito, Masaya
    Hayakawa, Sara
    Oguchi, Tomohiko
    Komai, Yoshinobu
    Numao, Noboru
    Yuasa, Takeshi
    Inoue, Masaharu
    Ushijima, Hiroki
    Kudo, Shigehiro
    Shimano, Yasumasa
    Nakamura, Yuki
    Uchida, Yusuke
    Uehara, Sho
    Tanaka, Hajime
    Yaegashi, Hiroshi
    Izumi, Kouji
    Yokoyama, Minato
    Matsuoka, Yoh
    Yoshioka, Yasuo
    Konishi, Koji
    Nakanishi, Katsuyuki
    Nagahara, Akira
    Hirakawa, Akihiro
    Koike, Ryuji
    Koga, Fumitaka
    Nishimura, Kazuo
    Mizokami, Atsushi
    Yonese, Junji
    Kageyama, Yukio
    Yoshimura, Ryoichi
    Fujii, Yasuhisa
    BMC UROLOGY, 2023, 23 (01)
  • [39] A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)
    Soichiro Yoshida
    Taro Takahara
    Yuki Arita
    Masaya Ito
    Sara Hayakawa
    Tomohiko Oguchi
    Yoshinobu Komai
    Noboru Numao
    Takeshi Yuasa
    Masaharu Inoue
    Hiroki Ushijima
    Shigehiro Kudo
    Yasumasa Shimano
    Yuki Nakamura
    Yusuke Uchida
    Sho Uehara
    Hajime Tanaka
    Hiroshi Yaegashi
    Kouji Izumi
    Minato Yokoyama
    Yoh Matsuoka
    Yasuo Yoshioka
    Koji Konishi
    Katsuyuki Nakanishi
    Akira Nagahara
    Akihiro Hirakawa
    Ryuji Koike
    Fumitaka Koga
    Kazuo Nishimura
    Atsushi Mizokami
    Junji Yonese
    Yukio Kageyama
    Ryoichi Yoshimura
    Yasuhisa Fujii
    BMC Urology, 23
  • [40] Axitinib plus avelumab for recurrent/metastatic adenoid cystic carcinoma (R/M ACC): Biomarker analysis of the phase II trial
    Hoff, Camilla Oliveira
    McGrail, Daniel
    Mitani, Yoshitsugu
    Heeke, Simon
    Sousa, Luana
    Santos, Erison
    Siqueira, Juliana Mota
    Li, Kaiyi
    Bell, Diana
    Marques-Piubelli, Mario L.
    Lin, Shiaw-Yih
    El-Naggar, Adel K.
    Ferrarotto, Renata
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345